PAH rs121908252: Understanding the c.1066-11G>A Variant
The variant rs121908252, also known as c.1066-11G>A, is a genetic alteration in the PAH gene associated with carrier status for phenylketonuria (PKU). It is a splice-site variant that can affect how the body processes the amino acid phenylalanine.
What each genotype means
Typical enzyme activity
You carry two copies of the common G allele at this position, indicating that you do not carry the c.1066-11G>A splice-site alteration. This genotype is associated with normal phenylalanine hydroxylase function at this specific site. It does not rule out being a carrier for other distinct variants in the PAH gene.
Carried by more than 99% of individuals across most global populations.
Phenylketonuria carrier
You carry one copy of the c.1066-11G>A variant, meaning you are an asymptomatic carrier for autosomal recessive phenylketonuria (PKU). Carriers typically have sufficient phenylalanine hydroxylase enzyme activity and do not exhibit clinical symptoms or require dietary changes. However, there is a risk of passing this variant to future offspring, which is relevant if a partner also carries a pathogenic PAH variant.
Found in approximately 1 in 200 to 1 in 500 individuals of Southern European and Mediterranean descent, but is very rare in East Asian and African ancestries.
Classic phenylketonuria risk
You carry two copies of the c.1066-11G>A splice-site alteration, historically known as the severe 'Mediterranean' variant. In clinical studies, this homozygous genotype results in near-complete loss of phenylalanine hydroxylase activity and is strongly associated with classic phenylketonuria. Individuals with this genotype generally require lifelong management of dietary phenylalanine intake under specialist metabolic care.
Extremely rare in the general population, primarily detected in clinical cohorts where it accounts for roughly 2% to 5% of diagnosed PKU cases in parts of Southern Europe and the Middle East.
What is the rs121908252 Variant?
The variant rs121908252 is a specific change in the DNA sequence of the PAH gene, located on chromosome 12. In scientific literature, it is frequently referred to by its nomenclature c.1066-11G>A. This notation indicates a change from a guanine (G) to an adenine (A) base at a position 11 nucleotides upstream of the start of exon 11. Because this location is within an intron—a non-coding region of the gene—it acts as a splice-site variant. Splice sites are critical "instructions" that tell the cellular machinery where to cut and join segments of messenger RNA (mRNA) during the process of gene expression. When this site is altered, the cell may incorrectly process the mRNA, often leading to the production of a non-functional or unstable protein.
The Role of the PAH Gene
The PAH gene provides instructions for making an enzyme called phenylalanine hydroxylase. This enzyme is primarily active in the liver and is responsible for converting the amino acid phenylalanine, which is obtained through the diet, into another amino acid called tyrosine. Tyrosine is essential for the production of neurotransmitters and other vital molecules in the body. When the PAH enzyme is absent or not functioning correctly, phenylalanine cannot be processed efficiently and begins to accumulate in the blood and tissues. High levels of phenylalanine are toxic to the nervous system, which is the underlying cause of phenylketonuria (PKU). The severity of the condition often depends on how much residual activity the enzyme retains, which is influenced by the specific genetic variants inherited.
Research and Clinical Associations
Research has established that rs121908252 is a pathogenic variant associated with PKU. Because PKU is an autosomal recessive condition, an individual typically needs to inherit two pathogenic variants—one from each parent—to manifest the clinical symptoms of the disorder. Carriers, who possess only one copy of this variant, generally do not exhibit symptoms of PKU because their other copy of the PAH gene is usually functional enough to maintain normal phenylalanine metabolism. Studies have shown that this specific splice-site mutation can lead to the insertion of extra genetic material into the mRNA, resulting in a protein that lacks catalytic activity. While the evidence linking this variant to PKU is strong, the clinical outcome for any individual is determined by the combination of both inherited alleles, as the milder of the two often dictates the final phenotype.
Population Frequency and Distribution
The prevalence of the rs121908252 variant is not uniform across the globe; it shows distinct geographic clustering. It is particularly prevalent in Mediterranean and Southern European populations, including regions of Italy and Turkey. In these areas, the variant has been identified as a significant contributor to the local allelic pool of PAH mutations. Because of these historical migration patterns and founder effects, the frequency of this variant is higher in these specific ancestral groups compared to the general global population. Understanding this distribution is important for genetic screening programs, as it helps clinicians identify populations where testing for this specific variant may be more informative for carrier screening.
What This Information Means for You
If you have received information regarding your status for rs121908252, it is important to understand that this is a carrier status marker. Being a carrier does not mean you have PKU, nor does it mean you will develop it. However, if you are planning a family, you may wish to discuss your carrier status with a genetic counselor. They can provide context on the likelihood of passing this variant to children and explain the implications if your partner is also a carrier. This information is for educational purposes and should not be used to make medical decisions. Always consult with a qualified healthcare professional or a medical geneticist to interpret your specific genetic results and understand what they mean for your health or family planning.
How common is this variant?
The rs121908252 variant is notably prevalent in Mediterranean and Southern European populations, where it represents a significant portion of the local PAH mutation spectrum.
Frequently asked questions
Is rs121908252 the same as having PKU?
No, having this variant does not automatically mean you have PKU. PKU is an autosomal recessive condition, meaning it typically requires two pathogenic variants to manifest symptoms.
What should I do if I am a carrier of this variant?
Being a carrier is generally asymptomatic. If you are planning a family, you should speak with a genetic counselor to understand the risks and options for carrier testing for your partner.
Can I change my genotype for this variant?
No, your genetic sequence is inherited from your parents and cannot be changed. Genetic testing provides information about your biological makeup, not a condition that can be altered.
Where can I get more information about my specific results?
You should consult with your primary care physician or a board-certified genetic counselor. They can interpret your results in the context of your personal and family medical history.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908252?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PAH
Pathogenic missense variant (p.Arg408Trp) associated with phenylketonuria (PKU).
Pathogenic phenylalanine hydroxylase variant conferring risk of phenylketonuria.
A severe pathogenic missense variant (p.Arg408Trp) in the PAH gene associated with phenylketonuria.
Missense variant (c.1222C>T, p.Arg408Trp) that disrupts phenylalanine hydroxylase activity, associated with phenylketonuria.
Splice-site variant (c.1066-11G>A) causing phenylalanine hydroxylase deficiency.
Missense variant (p.Arg408Trp) causing severe classic phenylketonuria (PKU) when inherited bi-allelically due to profound loss of phenylalanine hydroxylase activity.